

### EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment, to better clarify the invention, was given in a telephone interview with Lars Geneiser on 6/8/11.

The application has been amended as follows:

Claim 1) A method of examining the physiological effect of a compound on a mammalian prostate cancer cell, comprising:

(a) contacting said compound to be tested with said mammalian prostate cancer cell, wherein said mammalian prostate cancer cell has been selected as stably expressing an exogenous ~~wild-type~~ androgen receptor polynucleotide that encodes an androgen receptor protein or polypeptide or an androgen receptor protein or polypeptide variant, such that a total level of mRNA in the cell that encodes said androgen receptor protein or polypeptide or said androgen receptor protein or polypeptide variant, or a total protein or polypeptide level of said androgen receptor protein or polypeptide or said androgen receptor protein or polypeptide variant, is at least two-fold higher than the endogenous level of androgen receptor mRNA or protein or polypeptide in a hormone-sensitive prostate cancer cell, and wherein growth of said mammalian prostate cancer cell is hormone refractory, to provide a treated prostate cancer cell;

(b) comparing one or more physiological characteristics of said treated prostate cancer cell with the same one or more characteristics of a control prostate cancer cell to which said compound has not been administered; and

(c) determining from a difference in the one or more characteristics whether said compound has a physiological effect on the treated prostate cancer cell, decreases the biological function of androgen receptors, and/or inhibits the growth of hormone-refractory prostate cancer cells.

Claim 6) **Cancel**

Claim 8) **Cancel**

Claim 10) **Cancel**

Claim 16) **Cancel**

Claim 17) **Cancel**

Claim 18) **Cancel**

Claim 19) **Cancel**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN AEDER whose telephone number is (571)272-8787. The examiner can normally be reached on M-F: 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Misook Yu can be reached on 571-272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Sean E Aeder/  
Primary Examiner, Art Unit 1642